EU approves marketing of dupilumab for atopic dermatitis


eMediNexus    02 October 2017

The European Commission has granted marketing authorization to dupilumab (Dupixent, Samofi and Regeneron), a human monoclonal antibody, for adults with moderate to severe atopic dermatitis, to be used with or without topical corticosteroids. Dupilumab will be available in a premixed syringe for biweekly injection.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.